3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neuralgia
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Gemcitabine
12
Mitomycin
11
Cisplatin
10
Carboplatin
8
pembrolizumab
7
Docetaxel
4
toripalimab
3
avelumab
3
atezolizumab
3
Paclitaxel
3
sacituzumab govitecan
2
disitamab vedotin
2
Taxes
2
Specimen Handling
2
Platinum
2
Magnetic Resonance Spectroscopy
2
Injections
2
1,2-diaminocyclohexaneplatinum II citrate
2
vinflunine
1
valrubicin
1
tislelizumab
1
lenvatinib
1
eribulin
1
epacadostat
1
enfortumab vedotin
1
durvalumab
1
dodecyl maltoside
1
Vitamin B 12
1
Standard of Care
1
Ramucirumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Transitional Cell
×
Vitamin B 12
×
Clear all
NCT03193788
2017-06-21
PREMIER
Asan Medical Center
Phase 3
Unknown
74 enrolled